Navidea Biopharmaceuticals Inc (NAVB)
0.035
0.00 (0.00%)
USD |
OTCM |
May 07, 09:30
Navidea Biopharmaceuticals Cash from Financing (Quarterly): -0.1886M for Sept. 30, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | -0.1886M |
| June 30, 2023 | 1.485M |
| March 31, 2023 | -0.2005M |
| December 31, 2022 | -0.0998M |
| September 30, 2022 | 6.210M |
| June 30, 2022 | 1.371M |
| March 31, 2022 | -0.3395M |
| December 31, 2021 | -0.1275M |
| September 30, 2021 | 2.208M |
| June 30, 2021 | 2.061M |
| March 31, 2021 | 7.967M |
| December 31, 2020 | 1.587M |
| September 30, 2020 | 4.944M |
| June 30, 2020 | 3.109M |
| March 31, 2020 | 0.57M |
| December 31, 2019 | 0.997M |
| September 30, 2019 | -0.08M |
| June 30, 2019 | 5.306M |
| March 31, 2019 | -0.067M |
| December 31, 2018 | -0.0774M |
| September 30, 2018 | 2.920M |
| June 30, 2018 | -7.272M |
| March 31, 2018 | -0.1181M |
| December 31, 2017 | -0.0601M |
| September 30, 2017 | -0.0447M |
| Date | Value |
|---|---|
| June 30, 2017 | -0.1319M |
| March 31, 2017 | -60.76M |
| December 31, 2016 | -1.529M |
| September 30, 2016 | -3.001M |
| June 30, 2016 | -4.614M |
| March 31, 2016 | -0.0007M |
| December 31, 2015 | -0.0007M |
| September 30, 2015 | -0.3289M |
| June 30, 2015 | 17.62M |
| March 31, 2015 | 3.500M |
| December 31, 2014 | -0.0554M |
| September 30, 2014 | -0.0006M |
| June 30, 2014 | 0.0152M |
| March 31, 2014 | 3.232M |
| December 31, 2013 | -0.0369M |
| September 30, 2013 | 28.80M |
| June 30, 2013 | 23.48M |
| March 31, 2013 | 8.480M |
| December 31, 2012 | 5.274M |
| September 30, 2012 | -0.4324M |
| June 30, 2012 | 0.2353M |
| March 31, 2012 | -0.0074M |
| December 31, 2011 | 6.528M |
| September 30, 2011 | 0.7554M |
| June 30, 2011 | -1.342M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.3395M
Minimum
Mar 2022
7.967M
Maximum
Mar 2021
2.043M
Average
1.428M
Median
Cash from Financing (Quarterly) Benchmarks
| Perspective Therapeutics Inc | 0.352M |
| Electromed Inc | 0.026M |
| Xtant Medical Holdings Inc | 0.325M |
| Asensus Surgical Inc | 0.172M |
| Senseonics Holdings Inc | -1.178M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -10.25M |
| Cash from Investing (Quarterly) | -0.5247M |
| Free Cash Flow | -9.907M |
| Free Cash Flow Per Share (Quarterly) | -0.1033 |
| Free Cash Flow Yield | -532.4% |